Literature DB >> 31843189

Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded.

Hemamali Samaratunga1, Brett Delahunt2, Lars Egevad3, John R Srigley4, Athanase Billis5, David G Bostwick6, Philippe Camparo7, Liang Cheng8, David Clouston9, James Denham10, Bungo Furusato11, Arndt Hartmann12, Laura Jufe13, James Kench14, Diane N Kenwright15, Glen Kristiansen16, Katia R M Leite17, Gregory T MacLennan18, Jennifer Merrimen19, Holger Moch20, Jon Oxley21, Chin-Chen Pan22, Gladell Paner23, Jae Ro24, Isabell A M Sesterhenn25, Jonathan Shanks26, Michelle Thunders15, Toyonori Tsuzuki27, Thomas Wheeler28, John W Yaxley29, Murali Varma30.   

Abstract

Infiltration of the prostatic ducts by prostatic adenocarcinoma occurs relatively frequently, being most commonly associated with high grade disease. It is now recognised that intraductal carcinoma of the prostate (IDCP) has an associated poor prognosis and this is reflected in its histological, molecular and immunohistochemical features. The current recommendation of the World Health Organization is that IDCP not be taken into consideration when grading prostate adenocarcinoma. It is apparent that Gleason did not differentiate between IDCP and stromal invasive carcinoma when developing and validating his grading system, and recent studies suggest that the incorporation of IDCP grading into the overall grading of the specimen provides additional prognostic information.
Copyright © 2019 Royal College of Pathologists of Australasia. All rights reserved.

Entities:  

Keywords:  ISUP grade; Prostate adenocarcinoma; intraductal carcinoma of prostate; prognosis

Year:  2019        PMID: 31843189     DOI: 10.1016/j.pathol.2019.11.001

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  4 in total

1.  Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma.

Authors:  Emily Chan; Jesse K McKenney; Sarah Hawley; Dillon Corrigan; Heidi Auman; Lisa F Newcomb; Hilary D Boyer; Peter R Carroll; Matthew R Cooperberg; Eric Klein; Ladan Fazli; Martin E Gleave; Antonio Hurtado-Coll; Jeffry P Simko; Peter S Nelson; Ian M Thompson; Maria S Tretiakova; Dean Troyer; Lawrence D True; Funda Vakar-Lopez; Daniel W Lin; James D Brooks; Ziding Feng; Jane K Nguyen
Journal:  Mod Pathol       Date:  2022-02-10       Impact factor: 8.209

Review 2.  WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer.

Authors:  James G Kench; Mahul B Amin; Daniel M Berney; Eva M Compérat; Ian A Cree; Anthony J Gill; Arndt Hartmann; Santosh Menon; Holger Moch; George J Netto; Maria R Raspollini; Mark A Rubin; Puay Hoon Tan; Toyonori Tsuzuki; Samra Turjalic; Theo H van der Kwast; Ming Zhou; John R Srigley
Journal:  Histopathology       Date:  2022-08-02       Impact factor: 7.778

3.  Intraductal carcinoma has a minimal impact on Grade Group assignment in prostate cancer biopsy and radical prostatectomy specimens.

Authors:  L Lucia Rijstenberg; Tim Hansum; Eva Hollemans; Charlotte F Kweldam; Intan P Kümmerlin; Chris H Bangma; Theodorus H van der Kwast; Monique J Roobol; Geert J L H van Leenders
Journal:  Histopathology       Date:  2020-09-11       Impact factor: 5.087

4.  Prostate cancer grading, time to go back to the future.

Authors:  Lars Egevad; Brett Delahunt; David G Bostwick; Liang Cheng; Andrew J Evans; Troy Gianduzzo; Markus Graefen; Jonas Hugosson; James G Kench; Katia R M Leite; Jon Oxley; Guido Sauter; John R Srigley; Pär Stattin; Toyonori Tsuzuki; John Yaxley; Hemamali Samaratunga
Journal:  BJU Int       Date:  2020-11-27       Impact factor: 5.588

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.